Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Organon & Co’s stock clocked out at $9.28, down -1.69% from its previous closing price of $9.44. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 5.1 million shares were traded. OGN stock price reached its highest trading level at $9.565 during the session, while it also had its lowest trading level at $9.24.
Ratios:
To gain a deeper understanding of OGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 12.14 whereas as Long-Term Debt/Eq ratio is at 11.98.
On September 06, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also upped its target price recommendation from $18 to $20.
Goldman Downgraded its Buy to Neutral on November 03, 2023, whereas the target price for the stock was revised from $33 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 14 ’25 when COX CARRIE SMITH bought 12,469 shares for $8.07 per share. The transaction valued at 100,591 led to the insider holds 12,469 shares of the business.
Falcione Aaron bought 5,500 shares of OGN for $48,235 on May 07 ’25. The Chief Human Resources Officer now owns 62,974 shares after completing the transaction at $8.77 per share. On May 06 ’25, another insider, Weaver Kirke, who serves as the Gen. Counsel & Corp. Secy. of the company, bought 8,045 shares for $9.21 each. As a result, the insider paid 74,054 and bolstered with 52,489 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 2412484352 and an Enterprise Value of 10709480448. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.45, and their Forward P/E ratio for the next fiscal year is 2.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 3.29. Its current Enterprise Value per Revenue stands at 1.705 whereas that against EBITDA is 6.386.
Stock Price History:
The Beta on a monthly basis for OGN is 0.56, which has changed by -0.5538461 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $23.10, while it has fallen to a 52-week low of $8.01. The 50-Day Moving Average of the stock is -4.56%, while the 200-Day Moving Average is calculated to be -27.94%.
Shares Statistics:
It appears that OGN traded 4.38M shares on average per day over the past three months and 5533450 shares per day over the past ten days. A total of 259.96M shares are outstanding, with a floating share count of 259.01M. Insiders hold about 0.37% of the company’s shares, while institutions hold 84.20% stake in the company. Shares short for OGN as of 1753920000 were 15006377 with a Short Ratio of 3.43, compared to 1751241600 on 15917721. Therefore, it implies a Short% of Shares Outstanding of 15006377 and a Short% of Float of 7.6899999999999995.
Earnings Estimates
The current rating of Organon & Co (OGN) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.9, with high estimates of $1.05 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.94 and $3.69 for the fiscal current year, implying an average EPS of $3.84. EPS for the following year is $4.06, with 6.0 analysts recommending between $4.26 and $3.83.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $1.56B. It ranges from a high estimate of $1.59B to a low estimate of $1.52B. As of the current estimate, Organon & Co’s year-ago sales were $1.58BFor the next quarter, 4 analysts are estimating revenue of $1.59B. There is a high estimate of $1.64B for the next quarter, whereas the lowest estimate is $1.53B.
A total of 6 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.33B, while the lowest revenue estimate was $6.14B, resulting in an average revenue estimate of $6.26B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.31B in the next fiscal year. The high estimate is $6.41B and the low estimate is $6.13B.
